Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.
Heinz Gisslinger, MD
Advertisement
Articles by Heinz Gisslinger, MD
Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.
Advertisement
Latest Updated Articles
Dr. Gisslinger on a Study Comparing Ropeginterferon Alfa-2b to Hydroxyurea in PVPublished: December 6th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5